SOURCE: annual_report_text (1).txt
CHUNK: 535 of 1106
SIZE: 567 characters
PREVIOUS: chunk_0534_annual_report_text (1).txt
NEXT: chunk_0536_annual_report_text (1).txt
------------------------------
branch will 
be dissolved in 2024. The branches were 
established as part of the Companys Proton 
Therapy business (section 3:6, 1, 5, of the 
BCAC). The 2023 profit amounts to EUR 13.8 million, the 
profit carried forward from the previous years is 
EUR 119.0 million, making a total profit for 
appropriation of EUR 132.8 million. An unavailable reserve for the own shares needs 
to be recognised, impact of EUR 12.7 million 
this increased the Retained Earnings to the 
amount mentioned above with EUR 4.5 million 
(share price decreased compared to end of 
2022).